Astellas Pharma Inc. (ALPMF)

9,52 0,00 (0,00%) Ab 03:37PM EDT. Markt geöffnet.

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
https://www.astellas.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Naoki Okamura BSc	President, CEO & Director	953,82k	N/A	1962
Mr. Atsushi Kitamura	Chief Financial Officer	N/A	N/A	N/A
Nobue Yasuda	General Manager of Finance & Accounting Department	N/A	N/A	N/A
Mr. Yoshitsugu Shitaka Ph.D.	Chief Scientific Officer & Senior Managing Executive Officer	N/A	N/A	N/A
Ms. Catherine B. Levitt	General Counsel	N/A	N/A	N/A
Mr. Katsuyoshi Sugita	Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director	N/A	N/A	1967
Mr. Stig Ogata	Vice President of Corporate Communications	N/A	N/A	N/A
Ms. Collette Taylor	Senior Vice President of Human Resources	N/A	N/A	1963
Ms. Tatjana Dragovic	Senior VP and Head of Ethics & Compliance	N/A	N/A	N/A
Mr. Nobuaki Tanaka	President of Japan Commercial & Senior Corporate Executive	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Corporate Governance

Astellas Pharma Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 2. Die grundlegenden Scores sind Audit: 1, Vorstand: 2, Shareholderrechte: 6, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.